MeMed’s COVID-19 Severity Test Receives CE Mark for Predicting Severe Outcomes in COVID-19 Patients
27 juil. 2021 02h00 HE
|
MeMed
MeMed’s COVID-19 Severity Test Receives CE Mark for Predicting Severe Outcomes in COVID-19 PatientsMeMed COVID-19 Severity reads the immune-system in real time to accurately determine whether...
MeMed Key® Wins Red Dot Award for High Design Quality
22 avr. 2021 07h00 HE
|
MeMed
MeMed Key® Wins Red Dot Award for High Design Quality HAIFA, April 22, 2021- frog, a leading global design and strategy consultancy, part of...
MeMed and 360Dx Bring Together International Experts for a Timely Discussion on Predicting COVID-19 Severity Using the Host Immune Response
13 avr. 2021 07h00 HE
|
MeMed
MeMed and 360Dx Bring Together International Experts for a Timely Discussion on Predicting COVID-19 Severity Using the Host Immune Response HAIFA, Israel, April 13, 2021 – MeMed, a leader in...
Troy Boutelle Joins MeMed as Vice President of Commercial in North America and General Manager, U.S.
12 janv. 2021 07h00 HE
|
MeMed
Troy Boutelle Joins MeMed as Vice President of Commercial in North America and General Manager, U.S. Troy brings 20 years of top-flight sales and commercial experience as MeMed expands into the U.S....
MeMed Appoints Industry Veteran Chris Hibberd to its Board of Directors
16 déc. 2020 07h12 HE
|
MeMed
MeMed Appoints Industry Veteran Chris Hibberd to its Board of Directors HAIFA, Israel, December 16, 2020 – MeMed, a leader in host immune response-based solutions, today announced that Chris Hibberd...
MeMed Selected to Present at BARDA Industry Day 2020
26 oct. 2020 07h00 HE
|
MeMed
MeMed Selected to Present at BARDA Industry Day 2020 Dr. Eran Eden to Give Lightning Talk on October 27 on MeMed’s Advanced Host-Immune Response Technology HAIFA, Israel, October 26, 2020 – MeMed™,...
DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution
08 sept. 2020 07h00 HE
|
MeMed
DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution ...
DiaSorin 与 MeMed 合作开发和商业化基于新型宿主免疫应答的诊断解决方案
08 sept. 2020 02h02 HE
|
MeMed
DiaSorin 与 MeMed 合作开发和商业化基于新型宿主免疫应答的诊断解决方案 ...
DiaSorin e MeMed avviano una partnership strategica per lo sviluppo e la commercializzazione di una soluzione diagnostica basata sulla risposta immunitaria dei pazienti
08 sept. 2020 01h30 HE
|
MeMed
DiaSorin e MeMed avviano una partnership strategica per lo sviluppo e la commercializzazione di una soluzione diagnostica basata sulla risposta immunitaria dei pazienti Accordo di licenza per...
DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution
08 sept. 2020 01h30 HE
|
MeMed
DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution ...